PriceTargets.com logo

ProKidney - PROK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.50
  • Forecasted Upside: 250.55%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.71 As of 04/25/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PROK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProKidney Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROK

Analyst Price Target is $9.50
▲ +250.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ProKidney in the last 3 months. The average price target is $9.50, with a high forecast of $16.00 and a low forecast of $3.00. The average price target represents a 250.55% upside from the last price of $2.71.

This chart shows the closing price for PROK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in ProKidney. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2024Morgan StanleyInitiated CoverageEqual Weight$3.00Low
1/2/2024Bank of AmericaDowngradeBuy ➝ NeutralLow
7/24/2023BTIG ResearchInitiated CoverageBuy$16.00Low
12/21/2022Jefferies Financial GroupInitiated CoverageBuy$15.00Low
11/10/2022Morgan StanleyInitiated CoverageEqual Weight$13.00Low
10/18/2022UBS GroupInitiated CoverageBuy$18.00Low
10/14/2022CitigroupInitiated CoverageBuy$16.00Low
9/23/2022Bank of AmericaInitiated CoverageBuy$14.00Low
9/2/2022Evercore ISIInitiated CoverageOutperformLow
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ProKidney logo
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Read More

Today's Range

Now: $2.71
Low: $2.47
High: $2.73

50 Day Range

MA: $1.69
Low: $1.28
High: $2.84

52 Week Range

Now: $2.71
Low: $1.12
High: $13.51

Volume

494,119 shs

Average Volume

684,315 shs

Market Capitalization

$621.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of ProKidney?

The following Wall Street research analysts have issued research reports on ProKidney in the last twelve months: Bank of America Co., BTIG Research, and Morgan Stanley.
View the latest analyst ratings for PROK.

What is the current price target for ProKidney?

2 Wall Street analysts have set twelve-month price targets for ProKidney in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 250.6%. BTIG Research has the highest price target set, predicting PROK will reach $16.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for ProKidney in the next year.
View the latest price targets for PROK.

What is the current consensus analyst rating for ProKidney?

ProKidney currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PROK, but not buy more shares or sell existing shares.
View the latest ratings for PROK.

What other companies compete with ProKidney?

Other companies that are similar to ProKidney include Prime Medicine, Novavax, Allogene Therapeutics, Valneva and Exscientia. Learn More about companies similar to ProKidney.

How do I contact ProKidney's investor relations team?

ProKidney's physical mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The company's listed phone number is 336-999-7028 and its investor relations email address is [email protected]. The official website for ProKidney is www.prokidney.com. Learn More about contacing ProKidney investor relations.